MBX
MBX Biosciences, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+20/100
Last price
56.92
▼ 1.62 (2.77%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
58.50
Prev close
58.54
Day high
59.23
Day low
55.34
Volume
366.62K
Market cap
$2.74B
P/E (TTM)
—
52W range
12.94 – 72.64
Day trading desk
Gap from prior close
-0.07%
Prior close 58.54
VWAP
56.28
+1.13% from price
Relative volume
0.53×
Quiet session
Session range
7.02%
55.34 – 59.22
Position in range
41%
Mid range
ATR (14D)
3.63
6.39% of price
Prior day high
59.26
PDH
Prior day low
56.42
PDL
Bid / ask spread
—
Quote not published
Session volume
298.88K
Avg 562.82K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.44%
-3.4%
1M
-7.78%
-8.9%
3M
-7.81%
-12.3%
6M
+88.54%
+70.4%
YTD
+80.47%
+66.2%
1Y
+241.04%
+224.6%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on MBX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+109.73K
Net buying
Buy transactions
4
180.94K shares
Sell transactions
4
71.21K shares
Net transactions
+8
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
1.36M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 4, 26 | AZOULAY SALOMON M.D. Officer |
SELL | 370 | $24.34K | Direct |
| Aug 3, 26 | HOERTER STEVEN L Chief Executive Officer |
STOCK | 71.00K | $0 | Direct |
| Aug 3, 26 | SMITHER JOHN W Chief Financial Officer |
STOCK | 28.00K | $0 | Direct |
| May 8, 26 | AZOULAY SALOMON M.D. Officer |
SELL | 70.00K | $2.69M | Direct |
| May 8, 26 | AZOULAY SALOMON M.D. Officer |
CONVERSION | 70.00K | $815.35K | Direct |
| May 6, 26 | HAWRYLUK P KENT Chief Executive Officer |
SELL | 607 | $17.93K | Direct |
| May 6, 26 | AZOULAY SALOMON M.D. Officer |
SELL | 231 | $6.82K | Direct |
| May 1, 26 | HOERTER STEVEN L Director |
STOCK | 11.94K | $0 | Direct |
| Mar 13, 26 | HAWRYLUK P KENT Chief Executive Officer |
BUY | 18.50K | $525.66K | Indirect |
| Feb 26, 26 | HAWRYLUK P KENT Chief Executive Officer |
CONVERSION | 28.77K | $460.29K | Direct |
| Feb 2, 26 | HAWRYLUK P KENT Chief Executive Officer |
STOCK | 35.25K | $0 | Direct |
| Feb 2, 26 | BARTRAM RICHARD B Chief Financial Officer |
STOCK | 15.00K | $0 | Direct |
| Feb 2, 26 | AZOULAY SALOMON M.D. Officer |
STOCK | 15.00K | $0 | Direct |
| Oct 24, 25 | HAWRYLUK P KENT Chief Executive Officer |
CONVERSION | 182.86K | $594.29K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AZOULAY SALOMON M.D. |
Officer | 14.40K | Sale |
BARTRAM RICHARD B |
Chief Financial Officer | 15.00K | Stock Award(Grant) |
GORDON CARL L |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
HAWRYLUK P KENT |
Chief Executive Officer | 1.21M | Sale |
HERON PATRICK J |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
HOERTER STEVEN L |
Chief Executive Officer | 102.94K | Stock Award(Grant) |
ORBIMED ADVISORS, L.L.C. |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
PESCOVITZ ORA H |
Director | 24.33K | Purchase |
SMITHER JOHN W |
Chief Financial Officer | 28.00K | Stock Award(Grant) |
Fundamentals
Market cap$2.74B
Enterprise value$2.33B
Revenue (TTM)—
Gross profit—
EBITDA$-117.66M
Net income$-104.29M
EPS (TTM)$-2.30
Free cash flow$-53.01M
Total cash$418.58M
Total debt$3.34M
Book value / share$8.54
Shares outstanding48.16M
Float30.99M
Short % of float11.98%
Dividend yield0.00%
Beta (5Y)0.10
Valuation & profitability ratios
Trailing P/E—
Forward P/E-14.32
PEG ratio—
Price / sales—
Price / book6.66
EV / revenue—
EV / EBITDA-19.77
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-33.17%
Return on assets-22.08%
Debt / equity0.82
Current ratio18.08
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $79.16M | $57.41M | $28.53M | $21.40M | +37.9% |
| Selling, general & admin | $18.90M | $10.78M | $6.78M | $3.76M | +75.3% |
| Total operating expense | $98.06M | $68.19M | $35.31M | $25.16M | +43.8% |
| Operating income | -$98.06M | -$68.19M | -$35.31M | -$25.16M | -43.8% |
| Net interest income | $11.08M | $6.27M | $2.75M | -$2.00K | +76.7% |
| Pre-tax income | -$86.97M | -$61.92M | -$32.56M | -$26.14M | -40.5% |
| Net income | -$86.97M | -$61.92M | -$32.56M | -$26.14M | -40.5% |
| Net income to common | -$86.97M | -$61.92M | -$32.56M | -$26.14M | -40.5% |
| Basic EPS | -2.38 | -5.82 | -1.02 | -0.82 | +59.1% |
| Diluted EPS | -2.38 | -5.82 | -1.02 | -0.82 | +59.1% |
| EBIT | -$98.06M | -$68.19M | -$35.31M | -$25.76M | -43.8% |
| EBITDA | -$97.81M | -$67.95M | -$35.15M | -$25.70M | -43.9% |
| Basic shares | 36.51M | 10.64M | 31.85M | 31.85M | +243.0% |
| Diluted shares | 36.51M | 10.64M | 31.85M | 31.85M | +243.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $75.29M | $49.35M | $30.52M | $24.21M | +52.6% |
| Cash & short-term investments | $373.70M | $262.15M | $80.68M | $42.46M | +42.6% |
| Total current assets | $381.54M | $267.29M | $83.47M | $44.21M | +42.7% |
| Property, plant & equipment | $3.22M | $1.20M | $665.00K | $842.00K | +168.7% |
| Total assets | $385.14M | $268.54M | $84.18M | $45.09M | +43.4% |
| Total current liabilities | $15.49M | $11.05M | $3.93M | $3.43M | +40.2% |
| Total debt | $596.00K | $171.00K | $324.00K | $461.00K | +248.5% |
| Total liabilities | $15.92M | $11.09M | $156.65M | $87.70M | +43.5% |
| Retained earnings | -$224.48M | -$137.50M | -$75.58M | -$43.02M | -63.2% |
| Shareholder equity | $369.22M | $257.44M | -$72.47M | -$42.60M | +43.4% |
| Working capital | $366.04M | $256.24M | $79.54M | $40.78M | +42.9% |
| Net tangible assets | $369.22M | $257.44M | -$72.47M | -$42.60M | +43.4% |
| Shares issued | 44.93M | 33.42M | 31.85M | 31.85M | +34.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$86.97M | -$61.92M | -$32.56M | -$26.14M | -40.5% |
| Depreciation & amortisation | $248.00K | $244.00K | $157.00K | $56.00K | +1.6% |
| Stock-based compensation | $8.68M | $5.22M | $2.04M | $306.00K | +66.2% |
| Change in working capital | $1.57M | $4.60M | -$735.00K | $1.29M | -65.7% |
| Operating cash flow | -$79.95M | -$54.68M | -$31.98M | -$23.12M | -46.2% |
| Capital expenditure | -$1.93M | -$874.00K | -$129.00K | -$441.00K | -120.7% |
| Investing cash flow | -$83.70M | -$160.59M | -$30.93M | -$11.41M | +47.9% |
| Financing cash flow | $189.59M | $234.10M | $69.22M | $46.06M | -19.0% |
| Free cash flow | -$81.88M | -$55.55M | -$32.11M | -$23.56M | -47.4% |
| End cash position | $75.29M | $49.35M | $30.52M | $24.21M | +52.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $30.98M | $18.47M | $19.76M | $19.27M | $17.72M | +67.7% |
| Selling, general & admin | $9.95M | $8.79M | $6.04M | $4.66M | $4.08M | +13.1% |
| Total operating expense | $40.93M | $27.27M | $25.80M | $23.93M | $21.80M | +50.1% |
| Operating income | -$40.93M | -$27.27M | -$25.80M | -$23.93M | -$21.80M | -50.1% |
| Net interest income | $3.84M | $3.75M | $3.73M | $2.31M | $2.39M | +2.3% |
| Pre-tax income | -$37.09M | -$23.52M | -$22.06M | -$21.62M | -$19.41M | -57.7% |
| Net income | -$37.09M | -$23.52M | -$22.06M | -$21.62M | -$19.41M | -57.7% |
| Net income to common | -$37.09M | -$23.52M | -$22.06M | -$21.62M | -$19.41M | -57.7% |
| Basic EPS | -0.78 | -0.50 | -0.49 | -0.63 | -0.58 | -56.0% |
| Diluted EPS | -0.78 | -0.50 | -0.49 | -0.63 | -0.58 | -56.0% |
| EBIT | -$40.93M | -$27.27M | -$25.80M | -$23.93M | -$21.80M | -50.1% |
| EBITDA | -$40.85M | -$27.20M | -$25.73M | -$23.88M | -$21.74M | -50.2% |
| Basic shares | 47.70M | 46.58M | 44.87M | 34.20M | 33.45M | +2.4% |
| Diluted shares | 47.70M | 46.58M | 44.87M | 34.20M | 33.45M | +2.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $54.12M | $45.21M | $75.29M | $223.13M | $39.78M | +19.7% |
| Cash & short-term investments | $418.58M | $439.98M | $373.70M | $391.67M | $224.91M | -4.9% |
| Total current assets | $427.86M | $448.54M | $381.54M | $397.50M | $229.19M | -4.6% |
| Property, plant & equipment | $7.42M | $3.59M | $3.22M | $2.52M | $2.28M | +107.0% |
| Total assets | $435.91M | $452.70M | $385.14M | $400.08M | $231.52M | -3.7% |
| Total current liabilities | $23.66M | $14.57M | $15.49M | $12.06M | $11.76M | +62.4% |
| Total debt | $3.34M | $555.00K | $596.00K | $623.00K | $650.00K | +502.0% |
| Total liabilities | $26.37M | $14.95M | $15.92M | $12.54M | $12.28M | +76.4% |
| Retained earnings | -$285.09M | -$247.99M | -$224.48M | -$202.41M | -$180.80M | -15.0% |
| Shareholder equity | $409.54M | $437.76M | $369.22M | $387.54M | $219.24M | -6.4% |
| Working capital | $404.20M | $433.97M | $366.04M | $385.44M | $217.43M | -6.9% |
| Net tangible assets | $409.54M | $437.76M | $369.22M | $387.54M | $219.24M | -6.4% |
| Shares issued | 47.95M | 47.57M | 44.93M | 44.72M | 33.59M | +0.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$37.09M | -$23.52M | -$22.06M | -$21.62M | -$19.41M | -57.7% |
| Depreciation & amortisation | $79.00K | $64.00K | $60.00K | $50.00K | $61.00K | +23.4% |
| Stock-based compensation | $6.06M | $5.48M | $2.66M | $2.25M | $1.94M | +10.6% |
| Change in working capital | $8.63M | -$1.69M | $1.57M | -$1.51M | $918.00K | +609.5% |
| Operating cash flow | -$22.62M | -$20.21M | -$18.30M | -$21.54M | -$17.43M | -11.9% |
| Capital expenditure | -$901.00K | -$437.00K | -$793.00K | -$399.00K | -$707.00K | -106.2% |
| Investing cash flow | $29.21M | -$97.10M | -$129.97M | $17.06M | $25.99M | +130.1% |
| Financing cash flow | $2.32M | $87.44M | $438.00K | $187.82M | $1.33M | -97.3% |
| Free cash flow | -$23.52M | -$20.64M | -$19.09M | -$21.93M | -$18.14M | -13.9% |
| End cash position | $54.33M | $45.42M | $75.29M | $223.13M | $39.78M | +19.6% |
Options analytics
Put / call volume
0.61
Call-heavy session
Put / call open interest
3.86
Positioning, not flow
Max pain
45.00
-20.9% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
51
Contracts, this expiry
Put volume
31
Contracts, this expiry
Heaviest call OI
40.00
5 contracts
Heaviest put OI
30.00
10 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.59 | -0.78 | -33.2% |
| Mar 2026 | -0.58 | -0.51 | +12.2% |
| Dec 2025 | -0.60 | -0.49 | +17.9% |
| Sep 2025 | -0.68 | -0.63 | +7.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.84 | 7 | $0 | 0.0% |
| Next quarter | -0.93 | 7 | $0 | 0.0% |
| Current year | -3.05 | 8 | $0 | 0.0% |
| Next year | -3.98 | 8 | $0 | 0.0% |
Analyst targets & ownership
Mean target$94.30
High target$150.00
Low target$70.00
Implied upside65.67%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy3 / 8
Hold0
Sell / Strong sell0 / 0
Held by insiders2.82%
Held by institutions115.94%
Institutions holding240
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
57.13
-0.37% from price
SMA 20
59.30
-4.02% from price
SMA 50
63.03
-9.69% from price
SMA 100
54.18
+5.06% from price
SMA 200
43.80
+29.96% from price
EMA 12
58.27
-2.31% from price
EMA 26
59.71
-4.68% from price
EMA 50
59.56
-4.44% from price
RSI (14)
42.8
Neutral
MACD (12,26,9)
-1.45
Hist -0.04
ATR (14)
3.63
6.39% of price
Realised vol 30D
47.5%
Annualised
Bollinger upper
64.56
20, 2σ
Bollinger lower
54.05
20, 2σ
50 / 200 cross
Golden
63.03 vs 43.80
Trend bias
Above 200
+29.96%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.05
More volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
47.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-37.6%
Peak to trough
Max drawdown 5Y
-77.7%
Peak to trough
ATR 14
3.63
6.39% of price
Beta (reported)
0.10
5Y monthly, from filing
Short interest
Shares short
4.13M
Prior 4.95M
Change vs prior
-16.6%
Shorts covering
% of float
11.98%
Elevated
% of shares out
8.58%
Against total outstanding
Days to cover
10.5
Crowded exit
Float
30.99M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 10, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jul 29, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| May 12, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| May 12, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| May 11, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jan 28, 26 | Barclays | INITIATED | — | Overweight |
| Jan 16, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jan 7, 26 | UBS | INITIATED | — | Buy |
| Dec 19, 25 | Stifel | MAINTAINED | Buy | Buy |
| Dec 4, 25 | Goldman Sachs | INITIATED | — | Sell |
| Nov 10, 25 | Guggenheim | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-27
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-13
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-06-05
Corporate Changes & Voting Matters
8-K · 2026-05-11
Proxy Statements
DEFA14A · 2026-05-08
Corporate Changes & Voting Matters
8-K · 2026-05-07
Headlines
MBX Biosciences to Participate in Upcoming Investor Conferences
GlobeNewswire · 28d ago
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
GlobeNewswire · 29d ago
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
GlobeNewswire · 41d ago
UMH Properties and 4 More Stocks See Action From Activist Investors
Barrons.com · 53d ago
Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating
MT Newswires · 58d ago
MBX Biosciences Shares Lower After Q2 Loss Widens
MT Newswires · 62d ago
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
GlobeNewswire · 62d ago
Attovia Therapeutics Appoints John W. Smither to Board of Directors
GlobeNewswire · 84d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.